7821 related articles for article (PubMed ID: 10230579)
1. Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits?
Lindelöf B
Drug Saf; 1999 Apr; 20(4):289-97. PubMed ID: 10230579
[TBL] [Abstract][Full Text] [Related]
2. Incidence and profile of skin cancers in patients following ultraviolet phototherapy without psoralens: A retrospective cohort study.
Wang E; Ahad T; Liu YA; Lee TK; Lui H; Crawford RI; Kalia S
J Am Acad Dermatol; 2024 Apr; 90(4):759-766. PubMed ID: 38070541
[TBL] [Abstract][Full Text] [Related]
3. Effects of psoriasis and psoralen exposure on the somatic mutation landscape of the skin.
Olafsson S; Rodriguez E; Lawson ARJ; Abascal F; Huber AR; Suembuel M; Jones PH; Gerdes S; Martincorena I; Weidinger S; Campbell PJ; Anderson CA
Nat Genet; 2023 Nov; 55(11):1892-1900. PubMed ID: 37884686
[TBL] [Abstract][Full Text] [Related]
4. Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.
Geller S; Xu H; Lebwohl M; Nardone B; Lacouture ME; Kheterpal M
Am J Clin Dermatol; 2018 Jun; 19(3):363-375. PubMed ID: 29260411
[TBL] [Abstract][Full Text] [Related]
5. Psoriasis and cardiovascular risk: strength in numbers, part II.
Gelfand JM; Mehta NN; Langan SM
J Invest Dermatol; 2011 May; 131(5):1007-10. PubMed ID: 21494241
[TBL] [Abstract][Full Text] [Related]
6. Does the risk of basal cell carcinoma increase in patients with psoriasis under treatment?
Sevdem GA; Ozlem KS; Nazan Y; Nahide O
Photodermatol Photoimmunol Photomed; 2024 Mar; 40(2):e12956. PubMed ID: 38404169
[TBL] [Abstract][Full Text] [Related]
7. [Surgically treated malignant melanoma. The long-term results].
Meierovici D; Ceauşu M; Păun F
Chirurgia (Bucur); 1995; 44(4):69-71. PubMed ID: 8646029
[TBL] [Abstract][Full Text] [Related]
8. Frequency of U.V. induced protein-DNA crosslinks in cell lines of different sensitivities.
Gregg K; Mansbridge J
Int J Radiat Biol Relat Stud Phys Chem Med; 1981 Apr; 39(4):367-75. PubMed ID: 6971847
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies to human osteosarcoma-associated antigen(s).
Tsang KY; Warren RQ; Bishop L; Pathak S; Koger B; LaVia MF
J Natl Cancer Inst; 1986 Dec; 77(6):1175-80. PubMed ID: 3467110
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of trehalose-loaded liposomes against UVB-induced photodamage in human keratinocytes.
Emanuele E; Bertona M; Sanchis-Gomar F; Pareja-Galeano H; Lucia A
Biomed Rep; 2014 Sep; 2(5):755-759. PubMed ID: 25054023
[TBL] [Abstract][Full Text] [Related]
11. Metastasectomy and active specific immunotherapy for a large single melanoma metastasis.
Baars A; van Riel JM; Cuesta MA; Jaspars EH; Pinedo HM; van den Eertwegh AJ
Hepatogastroenterology; 2002; 49(45):691-3. PubMed ID: 12063971
[TBL] [Abstract][Full Text] [Related]
12. [Primary cutaneous CD30-positive anaplastic large cell lymphoma].
Shi Q; Xu X; Yin H; Zhou X; Zhang T; Sun G; Mikihiro S; Qian B
Zhonghua Bing Li Xue Za Zhi; 2001 Apr; 30(2):97-100. PubMed ID: 11866962
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells.
Pethiyagoda CL; Welch DR; Fleming TP
Clin Exp Metastasis; 2000; 18(5):391-400. PubMed ID: 11467771
[TBL] [Abstract][Full Text] [Related]
14. Effect of lipoprotein lipase activators bezafibrate and NO-1886, on B16 melanoma-induced cachexia in mice.
Kawamura I; Yamamoto N; Sakai F; Yamazaki H; Goto T
Anticancer Res; 1999; 19(5B):4099-103. PubMed ID: 10628360
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of pre-existing collagen bundles in primary cutaneous melanoma.
Smolle J; Hofmann-Wellenhof R; Pfaffentaler E; Fink-Puches R; Kerl H
Melanoma Res; 1998 Apr; 8(2):161-5. PubMed ID: 9610870
[TBL] [Abstract][Full Text] [Related]
16. Malignant melanoma in the CNS, subtyping and immunocytochemistry.
Bär H; Schlote W
Clin Neuropathol; 1997; 16(6):337-45. PubMed ID: 9401802
[TBL] [Abstract][Full Text] [Related]
17. Signal transduction by the oncogenic receptor tyrosine kinase Xmrk in melanoma formation of Xiphophorus.
Wellbrock C; Gómez A; Schartl M
Pigment Cell Res; 1997; 10(1-2):34-40. PubMed ID: 9170160
[TBL] [Abstract][Full Text] [Related]
18. Morphologic analysis of three-dimensional tumors developed in fibrin matrix and agar culture system.
Kumazawa H; Hess M; Koldovsky P
Pathobiology; 1993; 61(1):31-5. PubMed ID: 8216820
[TBL] [Abstract][Full Text] [Related]
19. Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: a new approach for tumor treatment?
Nieborowska-Skórska M; Nakashima M; Ratajczak M; Steplewski Z; Calabretta B; Skórski T
Folia Histochem Cytobiol; 1994; 32(1):35-40. PubMed ID: 8026602
[TBL] [Abstract][Full Text] [Related]
20. Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones.
Bernhard H; Karbach J; Wölfel T; Busch P; Störkel S; Stöckle M; Wölfel C; Seliger B; Huber C; Meyer zum Büschenfelde KH
Int J Cancer; 1994 Dec; 59(6):837-42. PubMed ID: 7989126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
